Pancreatic Tumor-Targeting Stemsome Therapeutics

Owing to the intrinsic ability of stem cells to target the tumor environment, stem-cell-membrane-functionalized nanocarriers can target and load active anticancer drugs. In this work, a strategy that focuses on stem cells that self-target pancreatic cancer cells is developed. In particular, malignant deep tumors such as pancreatic cancer cells, one of the intractable tumors that currently have no successful clinical strategy, are available for targeting and destruction. By gaining the targeting ability of stem cells against pancreatic tumor cells, stem cell membranes can encapsulate nano-polylactide-co-glycolide loaded with doxorubicin to target and reduce deep pancreatic tumor tissues. Considering the lack of known target proteins on pancreatic tumor cells, the suggested platform technology can be utilized for targeting any malignant tumors in which surface target receptors are unavailable.

Automated summary

Due to stem cells' ability to specifically target tumor environments, stem-cell-membrane-functionalized nanocarriers can be used for targeted delivery of active anticancer drugs. This study focuses on self-targeting pancreatic cancer cells using stem cells. By utilizing the targeting abilities of stem cells, nano-polylactide-co-glycolide loaded with doxorubicin can be encapsulated within stem cell membranes, leading to targeted reduction of deep pancreatic tumor tissues. This platform technology can be applied to malignant tumors lacking surface target receptors, such as pancreatic tumor cells.